Life Antibody (Leukemia Inhibitory Factor Antibody) - Dosing and Treatment Protocol
I cannot provide definitive dosing recommendations for "Life antibody" as a therapeutic agent because no FDA-approved anti-LIF antibody currently exists for clinical use, and the evidence provided consists primarily of investigational agents in early-phase trials without established treatment protocols.
Current Status of Anti-LIF Antibody Development
Investigational Agent: MSC-1 (AZD0171)
The most advanced anti-LIF antibody in clinical development is MSC-1 (AZD0171), which completed a Phase I first-in-human trial 1:
Dosing from Phase I Trial:
- Recommended Phase II Dose (RP2D): 1500 mg intravenously every 3 weeks (Q3W)
- Dose escalation range tested: 75-1500 mg IV Q3W
- Maximum tolerated dose was not reached
- Treatment continued until disease progression or unmanageable toxicity
Safety Profile:
- Well tolerated across all dose levels
- No dose-limiting toxicities identified
- Approximately 50% experienced treatment-related adverse events (TRAEs)
- No patient withdrawals due to TRAEs
- No objective tumor responses observed; 23.7% achieved stable disease
Preclinical/Research Context Only
The other anti-LIF antibodies mentioned in the evidence are not available for clinical use 2, 3, 4, 5:
- Humanized anti-LIF antibody (h-anti-LIF): Preclinical development only, tested in xenograft models 4
- Polyclonal anti-LIF antibodies: Used only in animal research models 2, 3
- Active immunization approaches: Experimental vaccine strategies in mouse models 5
Critical Clinical Considerations
Why This Matters for Practice
There is no approved "Life antibody" for clinical prescription. The term appears to be a misunderstanding or refers to investigational agents not yet available outside clinical trials. If you are considering anti-LIF therapy:
- Enrollment in clinical trials is the only current access route for MSC-1/AZD0171
- No standard-of-care dosing exists outside of trial protocols
- Combination therapy potential exists (preclinical data suggest synergy with checkpoint inhibitors and chemotherapy) 1, 4, but this remains investigational
Mechanism and Rationale
Anti-LIF antibodies work by:
- Blocking LIF-mediated immunosuppression in the tumor microenvironment
- Modulating tumor-associated macrophages (TAMs)
- Inhibiting cancer stem cells
- Potentially enhancing responses to chemotherapy and immunotherapy 1, 4
Confusion with VIGIV
Important distinction: The FDA-approved product in the evidence is VIGIV (Vaccinia Immune Globulin Intravenous) 6, which is completely unrelated to anti-LIF therapy. VIGIV is used for vaccinia virus complications, not cancer or LIF-related conditions.
VIGIV dosing (for reference only, not related to LIF):
- 6000 Units/kg IV for severe vaccinia complications
- Maximum infusion rate: 2 mL/min (or 0.04 mL/kg/min for patients <50 kg)
- Maximum daily dose for thrombosis risk: 12,000 Units/kg
Recommendation for Clinical Practice
If you are seeking anti-LIF therapy for a patient, you must:
- Identify active clinical trials investigating MSC-1 (AZD0171) or other anti-LIF antibodies
- Assess patient eligibility for trial enrollment
- Contact the trial sponsor or principal investigator for access
Do not attempt to use this therapy outside of a clinical trial setting, as no approved formulation, validated dosing regimen, or safety monitoring protocol exists for routine clinical use.